Etanercept provides a more physiological approach in the treatment of psoriasis

Gianfranco Altomare, Fabio Ayala, Enzo Berardesca, Sergio Chimenti, Alberto Giannetti, Giampiero Girolomoni, Torello Lotti, Patrizia Martini, Andrea Peserico, Antonio Puglisi Guerra, Gino A. Vena

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Psoriasis is a common chronic inflammatory disease affecting the skin and joints. Moderate to severe psoriasis is traditionally treated with systemic treatments, which can be effective but are often associated with relevant adverse effects, even when administered intermittently or rotationally. Biologic therapies may provide high and consistent efficacy over time, long-term safety, and simple administration schedules compared with nonbiologic therapies, and can be used in patients intolerant and/or resistant to these therapies. TNF-antagonists have a definite advantage over other biologic agents (e.g., T-cell targeting drugs) in the early and late manifestations of joint involvement. TNF-antagonists are a class of drugs with distinct pharmacokinetic and pharmacodynamic properties, and different safety profiles. Etanercept provides a more "physiological" mechanism of action compared to anti-TNF antibodies. Etanercept has less dramatic effects on TNF homeostasis although it has been proved to be highly effective in blocking psoriatic joint erosions. It maintains stable efficacy over time on skin psoriasis, also when used intermittently. Moreover, etanercept has been shown to be not immunogenic, and it only slightly increases the risk of granulomatous infections compared to anti-TNF antibodies. According to the "physiologic" paradigm of selection among TNF-antagonists linked to more or less physiologic mechanism of action, etanercept appears to be the anti-TNF of choice for treating most patients with moderate to severe plaque psoriasis and psoriatic arthritis, possibly even at an early stage.

Original languageEnglish
JournalDermatologic Therapy
Volume21
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Psoriasis
Joints
Anti-Idiotypic Antibodies
Safety
Skin
Psoriatic Arthritis
Biological Therapy
Biological Factors
Therapeutics
Drug Delivery Systems
Appointments and Schedules
Homeostasis
Chronic Disease
Pharmacokinetics
T-Lymphocytes
Etanercept
Infection
Pharmaceutical Preparations

Keywords

  • Adalimumab
  • Efalizumab
  • Etanercept
  • Infliximab
  • Psoriasis
  • TNF-α

ASJC Scopus subject areas

  • Dermatology

Cite this

Altomare, G., Ayala, F., Berardesca, E., Chimenti, S., Giannetti, A., Girolomoni, G., ... Vena, G. A. (2008). Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatologic Therapy, 21(SUPPL. 2). https://doi.org/10.1111/j.1529-8019.2008.00226.x

Etanercept provides a more physiological approach in the treatment of psoriasis. / Altomare, Gianfranco; Ayala, Fabio; Berardesca, Enzo; Chimenti, Sergio; Giannetti, Alberto; Girolomoni, Giampiero; Lotti, Torello; Martini, Patrizia; Peserico, Andrea; Guerra, Antonio Puglisi; Vena, Gino A.

In: Dermatologic Therapy, Vol. 21, No. SUPPL. 2, 09.2008.

Research output: Contribution to journalArticle

Altomare, G, Ayala, F, Berardesca, E, Chimenti, S, Giannetti, A, Girolomoni, G, Lotti, T, Martini, P, Peserico, A, Guerra, AP & Vena, GA 2008, 'Etanercept provides a more physiological approach in the treatment of psoriasis', Dermatologic Therapy, vol. 21, no. SUPPL. 2. https://doi.org/10.1111/j.1529-8019.2008.00226.x
Altomare, Gianfranco ; Ayala, Fabio ; Berardesca, Enzo ; Chimenti, Sergio ; Giannetti, Alberto ; Girolomoni, Giampiero ; Lotti, Torello ; Martini, Patrizia ; Peserico, Andrea ; Guerra, Antonio Puglisi ; Vena, Gino A. / Etanercept provides a more physiological approach in the treatment of psoriasis. In: Dermatologic Therapy. 2008 ; Vol. 21, No. SUPPL. 2.
@article{341e2142d82b4cf6840f7c1bfe3b2787,
title = "Etanercept provides a more physiological approach in the treatment of psoriasis",
abstract = "Psoriasis is a common chronic inflammatory disease affecting the skin and joints. Moderate to severe psoriasis is traditionally treated with systemic treatments, which can be effective but are often associated with relevant adverse effects, even when administered intermittently or rotationally. Biologic therapies may provide high and consistent efficacy over time, long-term safety, and simple administration schedules compared with nonbiologic therapies, and can be used in patients intolerant and/or resistant to these therapies. TNF-antagonists have a definite advantage over other biologic agents (e.g., T-cell targeting drugs) in the early and late manifestations of joint involvement. TNF-antagonists are a class of drugs with distinct pharmacokinetic and pharmacodynamic properties, and different safety profiles. Etanercept provides a more {"}physiological{"} mechanism of action compared to anti-TNF antibodies. Etanercept has less dramatic effects on TNF homeostasis although it has been proved to be highly effective in blocking psoriatic joint erosions. It maintains stable efficacy over time on skin psoriasis, also when used intermittently. Moreover, etanercept has been shown to be not immunogenic, and it only slightly increases the risk of granulomatous infections compared to anti-TNF antibodies. According to the {"}physiologic{"} paradigm of selection among TNF-antagonists linked to more or less physiologic mechanism of action, etanercept appears to be the anti-TNF of choice for treating most patients with moderate to severe plaque psoriasis and psoriatic arthritis, possibly even at an early stage.",
keywords = "Adalimumab, Efalizumab, Etanercept, Infliximab, Psoriasis, TNF-α",
author = "Gianfranco Altomare and Fabio Ayala and Enzo Berardesca and Sergio Chimenti and Alberto Giannetti and Giampiero Girolomoni and Torello Lotti and Patrizia Martini and Andrea Peserico and Guerra, {Antonio Puglisi} and Vena, {Gino A.}",
year = "2008",
month = "9",
doi = "10.1111/j.1529-8019.2008.00226.x",
language = "English",
volume = "21",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Blackwell Publishing Inc.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Etanercept provides a more physiological approach in the treatment of psoriasis

AU - Altomare, Gianfranco

AU - Ayala, Fabio

AU - Berardesca, Enzo

AU - Chimenti, Sergio

AU - Giannetti, Alberto

AU - Girolomoni, Giampiero

AU - Lotti, Torello

AU - Martini, Patrizia

AU - Peserico, Andrea

AU - Guerra, Antonio Puglisi

AU - Vena, Gino A.

PY - 2008/9

Y1 - 2008/9

N2 - Psoriasis is a common chronic inflammatory disease affecting the skin and joints. Moderate to severe psoriasis is traditionally treated with systemic treatments, which can be effective but are often associated with relevant adverse effects, even when administered intermittently or rotationally. Biologic therapies may provide high and consistent efficacy over time, long-term safety, and simple administration schedules compared with nonbiologic therapies, and can be used in patients intolerant and/or resistant to these therapies. TNF-antagonists have a definite advantage over other biologic agents (e.g., T-cell targeting drugs) in the early and late manifestations of joint involvement. TNF-antagonists are a class of drugs with distinct pharmacokinetic and pharmacodynamic properties, and different safety profiles. Etanercept provides a more "physiological" mechanism of action compared to anti-TNF antibodies. Etanercept has less dramatic effects on TNF homeostasis although it has been proved to be highly effective in blocking psoriatic joint erosions. It maintains stable efficacy over time on skin psoriasis, also when used intermittently. Moreover, etanercept has been shown to be not immunogenic, and it only slightly increases the risk of granulomatous infections compared to anti-TNF antibodies. According to the "physiologic" paradigm of selection among TNF-antagonists linked to more or less physiologic mechanism of action, etanercept appears to be the anti-TNF of choice for treating most patients with moderate to severe plaque psoriasis and psoriatic arthritis, possibly even at an early stage.

AB - Psoriasis is a common chronic inflammatory disease affecting the skin and joints. Moderate to severe psoriasis is traditionally treated with systemic treatments, which can be effective but are often associated with relevant adverse effects, even when administered intermittently or rotationally. Biologic therapies may provide high and consistent efficacy over time, long-term safety, and simple administration schedules compared with nonbiologic therapies, and can be used in patients intolerant and/or resistant to these therapies. TNF-antagonists have a definite advantage over other biologic agents (e.g., T-cell targeting drugs) in the early and late manifestations of joint involvement. TNF-antagonists are a class of drugs with distinct pharmacokinetic and pharmacodynamic properties, and different safety profiles. Etanercept provides a more "physiological" mechanism of action compared to anti-TNF antibodies. Etanercept has less dramatic effects on TNF homeostasis although it has been proved to be highly effective in blocking psoriatic joint erosions. It maintains stable efficacy over time on skin psoriasis, also when used intermittently. Moreover, etanercept has been shown to be not immunogenic, and it only slightly increases the risk of granulomatous infections compared to anti-TNF antibodies. According to the "physiologic" paradigm of selection among TNF-antagonists linked to more or less physiologic mechanism of action, etanercept appears to be the anti-TNF of choice for treating most patients with moderate to severe plaque psoriasis and psoriatic arthritis, possibly even at an early stage.

KW - Adalimumab

KW - Efalizumab

KW - Etanercept

KW - Infliximab

KW - Psoriasis

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=53149101296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149101296&partnerID=8YFLogxK

U2 - 10.1111/j.1529-8019.2008.00226.x

DO - 10.1111/j.1529-8019.2008.00226.x

M3 - Article

VL - 21

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - SUPPL. 2

ER -